Condition: Non-alcoholic Fatty Liver Disease (NAFLD) · Alcoholic Liver Disease (ALD) · Liver Fibrosis · Sponsor: University Hospital, Angers
The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.
This description comes directly from the study's public registry record.
William BELLANGER, PH · 02 41 73 58 10 · william.bellanger@univ-angers.fr
Marc De Saint Loup · 0241357812 · madesaintloup@chu-angers.fr
Always discuss trial participation with your own doctor first.
| ANGERS | Angers, France | Completed |
| CHU Angers | Angers, France | Active Not Recruiting |
| BAUGE | Baugé-en-Anjou, France | Recruiting |
| BECON | Bécon-les-Granits, France | Completed |
| Chalonnes | Chalonnes-sur-Loire, France | Completed |
| COMBOURG | Combourg, France | Completed |
| LIFFRE | Liffré, France | Completed |
| Montreuil | Montreuil-Bellay, France | Completed |
| RENNES - Armagnac, Churchill | Rennes, France | Completed |
| RENNES - Kennedy | Rennes, France | Completed |
| CHU Rennes | Rennes, France | Active Not Recruiting |
| SEGRE | Segré, France | Completed |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05699018